5 June 2017

ASX ANNOUNCEMENT

MVP signs significant Manufacturing Development Project with CSIRO.

Medical Developments International Limited (ASX: MVP) is delighted to announce it has signed an agreement with Australia’s preeminent science and research body the Commonwealth Scientific and Industrial Research Organisation (CSIRO) to develop new manufacturing technologies for pharmaceutical products.

This agreement extends MVP’s existing partnership with the CSIRO and the technologies developed in that partnership. Our collective ambition is to develop the next generation of manufacturing technologies to make “small molecule” pharmaceutical products at a significantly reduced cost and improved quality, compared with traditional processes. Work has already begun and the preliminary results are very encouraging.

MVP will invest up to $3m in this project over three years. MVP will fund the project as follows:

- Of the invoiced amount, 60% will be paid in cash or shares. If MVP choose to issue ordinary shares they will be issued at the 7 day Volume Weighted Average Price (VWAP); and
- The remaining 40% of the invoice is to be paid in cash. However the CSIRO has agreed to invest this portion of the fee by way of purchasing share Options. The Options will be unlisted and will have a term of 10 years. The Options can only be exercised / vested when a developed technology has been proven to be commercially viable. The Options will be issued at a 10% discount to the 7 day VWAP of the MVP share price at the date of invoice. Once the exercise conditions are met, each Option will vest into one fully paid MVP share.

Chief Executive Officer of MVP, Mr. John Sharman, said: “We are confident we can build on the success of the Penthrox project which delivered significant improvements to our existing manufacturing process. Our ambition is to create patentable intellectual property which will be owned by MVP. The CSIRO’s willingness to invest directly into MVP is a great indication of our collective confidence that we will be successful. Work has already begun and the preliminary results are very encouraging.”

Director of CSIRO Biomedical Manufacturing Group, Dr. Paul Savage, said: “CSIRO is delighted to partner with Medical Developments International to develop this new technology. We are confident that the approach used to develop MVP’s production technology for Penthrox can be extended to other pharmaceutical products. By introducing transformative processing technologies, CSIRO aims to further assist the global competitiveness and growth of the Australian pharmaceutical manufacturing industry.”

For more information:

John Sharman
Chief Executive Officer
03 9547 1888

Dr. Paul Savage
Director of CSIRO Biomedical Manufacturing Group
03 9545 2523
About Penthrox
Penthrox is a fast onset, non-opioid analgesic indicated for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. Penthrox has been used safely and effectively for more than 30 years in Australia with excess of 5.0 million units sold. There is growing interest in Penthrox being used in patients undergoing investigatory procedures, as well as operational procedures such as colonoscopy.

About Medical Developments International Ltd
MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Penthrox®, a fast acting trauma & emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defense Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.

About CSIRO
The Commonwealth Scientific and Industrial Research Organisation (CSIRO), work to shape the future. CSIRO does this by using science to solve real issues. Our research makes a difference to people, industry and the planet. CSIRO aim to innovate for tomorrow and help improve today – for our customers, all Australians and the world.

The CSIRO Biomedical Manufacturing Group work with biomedical companies to deliver new medical treatments and technologies that benefit millions of people in Australia and overseas, helping them live longer, healthier and more productive lives.